$627 Million is the total value of Rhenman & Partners Asset Management AB's 91 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 17.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Buy | Amgen Inc | $18,673,000 | +76.3% | 135,000 | +95.7% | 2.98% | +134.0% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $17,985,000 | -25.1% | 115,000 | -13.4% | 2.87% | -0.6% |
| MDT | Buy | Medtronic Plc | $17,739,000 | +54.6% | 265,000 | +71.2% | 2.83% | +105.2% |
| UNH | Sell | United Health Group Inc | $17,053,000 | -39.5% | 147,000 | -36.4% | 2.72% | -19.7% |
| LLY | Buy | Eli Lilly & Co | $15,483,000 | +6.0% | 185,000 | +5.7% | 2.47% | +40.6% |
| AET | Buy | Aetna Inc | $15,099,000 | +132.3% | 138,000 | +170.6% | 2.41% | +208.2% |
| ANTM | Buy | Anthem Inc | $14,980,000 | +57.4% | 107,000 | +84.5% | 2.39% | +108.9% |
| ALKS | Sell | Alkermes Plc | $14,961,000 | -33.4% | 255,000 | -26.9% | 2.38% | -11.6% |
| CELG | Sell | Celgene Corp | $14,711,000 | -7.2% | 136,000 | -0.7% | 2.34% | +23.2% |
| HUM | New | Humana Inc | $14,320,000 | – | 80,000 | +100.0% | 2.28% | – |
| CI | New | Cigna Corp | $14,299,000 | – | 105,900 | +100.0% | 2.28% | – |
| MCK | Buy | McKesson Corp | $14,247,000 | +153.5% | 77,000 | +208.0% | 2.27% | +236.4% |
| HCA | Buy | HCA Holdings Inc | $13,925,000 | +122.4% | 180,000 | +160.9% | 2.22% | +195.2% |
| PFE | New | Pfizer Inc | $13,224,000 | – | 421,000 | +100.0% | 2.11% | – |
| AGN | Buy | Allergan Plc | $12,503,000 | -1.9% | 46,000 | +9.5% | 1.99% | +30.2% |
| CAH | Sell | Cardinal Health Inc | $12,214,000 | -32.1% | 159,000 | -26.0% | 1.95% | -9.9% |
| BDX | Buy | Becton Dickinson & Co | $12,072,000 | +42.0% | 91,000 | +51.7% | 1.92% | +88.5% |
| INCY | Buy | Incyte Corp Ltd | $12,026,000 | +7.3% | 109,000 | +1.4% | 1.92% | +42.5% |
| STJ | Buy | St Jude Medical Inc | $11,987,000 | +97.6% | 190,000 | +128.9% | 1.91% | +162.5% |
| ABBV | Sell | AbbVie Inc | $11,426,000 | -27.0% | 210,000 | -9.9% | 1.82% | -3.1% |
| BMY | Sell | Bristol Myers Squibb Co | $11,366,000 | -13.7% | 192,000 | -3.0% | 1.81% | +14.5% |
| GILD | Sell | Gilead Sciences Inc | $11,292,000 | -25.8% | 115,000 | -11.5% | 1.80% | -1.5% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $10,935,000 | +61.0% | 105,000 | +90.9% | 1.74% | +113.6% |
| PRGO | Buy | Perrigo Co Plc | $10,223,000 | +17.7% | 65,000 | +38.3% | 1.63% | +56.3% |
| CNC | Buy | Centene Corp | $9,490,000 | +118.6% | 175,000 | +224.1% | 1.51% | +190.4% |
| CYH | Buy | Community Health Syst Inc | $9,409,000 | +35.8% | 220,000 | +100.0% | 1.50% | +80.3% |
| CVS | Sell | CVS Health Corp | $9,359,000 | -51.5% | 97,000 | -47.3% | 1.49% | -35.6% |
| BMRN | Sell | BioMarin Pharmaceutical Inc | $9,058,000 | -28.0% | 86,000 | -6.5% | 1.44% | -4.4% |
| HNT | New | Health Net Inc | $9,033,000 | – | 150,000 | +100.0% | 1.44% | – |
| EW | Buy | Edwards Lifesciences Corp | $8,815,000 | +121.0% | 62,000 | +121.4% | 1.40% | +193.3% |
| LH | Buy | Laboratory Corp of America Hgs | $8,786,000 | +3.5% | 81,000 | +15.7% | 1.40% | +37.5% |
| CEMP | Buy | Cempra Inc | $8,296,000 | -12.9% | 298,000 | +7.5% | 1.32% | +15.6% |
| ESRX | Buy | Express Scripts Hg Co | $7,772,000 | +10.6% | 96,000 | +21.5% | 1.24% | +46.8% |
| REGN | Sell | Regeneron Pharmaceuticals Inc | $7,675,000 | -20.8% | 16,500 | -13.2% | 1.22% | +5.2% |
| NKTR | Sell | Nektar Therapeutics | $7,540,000 | -35.7% | 688,000 | -26.6% | 1.20% | -14.6% |
| DXCM | Sell | Dexcom Inc | $7,212,000 | -2.0% | 84,000 | -8.7% | 1.15% | +30.1% |
| ABMD | Sell | Abiomed Inc | $7,050,000 | +3.1% | 76,000 | -26.9% | 1.12% | +36.9% |
| CERN | Buy | Cerner Corp | $6,955,000 | +21.3% | 116,000 | +39.8% | 1.11% | +61.2% |
| ITCI | Sell | Intra-Cellular Therapies Inc | $6,607,000 | +0.4% | 165,000 | -19.9% | 1.05% | +33.3% |
| ZBH | New | Zimmer Biomet Hgs Inc | $6,575,000 | – | 70,000 | +100.0% | 1.05% | – |
| ACAD | Buy | Acadia Pharmaceuticals Inc | $6,482,000 | -19.0% | 196,000 | +2.6% | 1.03% | +7.5% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $6,202,000 | -49.7% | 46,700 | -33.3% | 0.99% | -33.2% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $6,107,000 | -17.0% | 76,000 | +23.8% | 0.97% | +10.2% |
| UHS | Sell | Universal Health Services Inc B | $6,103,000 | -33.9% | 48,900 | -24.8% | 0.97% | -12.3% |
| ABC | Buy | AmerisourceBergen Corp | $5,984,000 | +34.0% | 63,000 | +50.0% | 0.95% | +78.0% |
| KERX | Buy | Keryx Biopharmaceuticals Inc | $5,502,000 | +3.2% | 1,563,000 | +192.7% | 0.88% | +37.0% |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $5,308,000 | -8.4% | 32,000 | +33.3% | 0.85% | +21.6% |
| ENDP | Buy | Endo International Plc | $5,057,000 | +7.7% | 73,000 | +23.8% | 0.81% | +42.9% |
| ZLTQ | Buy | ZELTIQ Aesthetics Inc | $5,029,000 | +32.3% | 157,000 | +21.7% | 0.80% | +75.5% |
| SUPN | Sell | Supernus Pharmaceuticals Inc | $4,957,000 | -30.0% | 353,328 | -15.3% | 0.79% | -7.1% |
| MRK | Sell | Merck & Co Inc | $4,939,000 | -66.6% | 100,000 | -61.5% | 0.79% | -55.7% |
| COO | Sell | Cooper Companies Inc (The) | $4,912,000 | -32.7% | 33,000 | -19.5% | 0.78% | -10.6% |
| MDVN | Buy | Medivation Inc | $4,845,000 | -7.8% | 114,000 | +147.8% | 0.77% | +22.3% |
| HTWR | Buy | Heartware Intl Inc | $4,551,000 | +298.9% | 87,000 | +454.1% | 0.73% | +429.9% |
| RVNC | Sell | Revance Therapeutics Inc | $4,404,000 | -19.9% | 148,000 | -14.0% | 0.70% | +6.2% |
| RAD | Sell | Rite Aid Corp | $4,037,000 | -73.4% | 665,000 | -63.4% | 0.64% | -64.7% |
| MYL | Buy | Mylan N.V. | $4,026,000 | -28.5% | 100,000 | +20.5% | 0.64% | -5.0% |
| CLVS | Sell | Clovis Oncology Inc | $3,954,000 | -26.0% | 43,000 | -29.2% | 0.63% | -1.7% |
| LBIO | Buy | Lion Biotechnologies Inc | $3,935,000 | -22.8% | 683,108 | +22.9% | 0.63% | +2.5% |
| CYBX | Sell | Cyberonics Inc | $3,464,000 | -41.7% | 57,000 | -43.0% | 0.55% | -22.7% |
| ISIS | Sell | Isis Pharmaceuticals Inc | $3,234,000 | -40.2% | 80,000 | -14.9% | 0.52% | -20.6% |
| KITE | Sell | Kite Pharma Inc | $3,174,000 | -21.1% | 57,000 | -13.6% | 0.51% | +4.8% |
| CLDX | Buy | Celldex Therapeutics Inc | $3,109,000 | -37.4% | 295,000 | +49.7% | 0.50% | -16.9% |
| PTLA | Sell | Portola Pharmaceuticals Inc | $3,026,000 | -12.6% | 71,000 | -6.6% | 0.48% | +15.9% |
| PODD | Buy | Insulet Corp | $2,850,000 | +2.2% | 110,000 | +22.2% | 0.45% | +35.5% |
| ELGX | Buy | Endologix Inc | $2,808,000 | +2.3% | 229,000 | +27.9% | 0.45% | +35.8% |
| OREX | Buy | Orexigen Therapeutics Inc | $2,509,000 | -35.8% | 1,189,000 | +50.7% | 0.40% | -14.7% |
| ARIA | Sell | Ariad Pharmaceuticals Inc | $2,511,000 | -32.5% | 430,000 | -4.4% | 0.40% | -10.5% |
| CATB | Buy | Catabasis Pharmaceuticals Inc | $2,430,000 | -25.0% | 300,427 | +13.2% | 0.39% | -0.5% |
| ESPR | Sell | Esperion Therapeutics Inc | $2,359,000 | -74.2% | 100,000 | -10.7% | 0.38% | -65.8% |
| MGNX | Macrogenics Inc | $2,312,000 | -43.6% | 107,959 | 0.0% | 0.37% | -25.0% | |
| HALO | Halozyme Therapeutics Inc | $2,310,000 | -40.5% | 172,000 | 0.0% | 0.37% | -21.0% | |
| CPHD | Cepheid Inc | $2,305,000 | -26.1% | 51,000 | 0.0% | 0.37% | -2.1% | |
| OMCL | Omnicell Inc | $2,301,000 | -17.6% | 74,000 | 0.0% | 0.37% | +9.6% | |
| RIGL | Rigel Pharmaceuticals Inc | $2,285,000 | -23.0% | 925,000 | 0.0% | 0.36% | +2.0% | |
| XNCR | Sell | Xencor Inc | $2,217,000 | -46.3% | 181,303 | -3.6% | 0.35% | -28.8% |
| LXRX | Buy | Lexicon Pharmaceuticals Inc | $2,148,000 | +56.1% | 200,000 | +17.0% | 0.34% | +107.3% |
| CMRX | Sell | Chimerix Inc | $2,139,000 | -29.8% | 56,000 | -15.2% | 0.34% | -6.8% |
| TSRO | Tesaro Inc | $2,041,000 | -31.8% | 50,899 | 0.0% | 0.32% | -9.5% | |
| ACHN | Achillion Pharmaceuticals Inc | $1,935,000 | -22.0% | 280,000 | 0.0% | 0.31% | +3.4% | |
| TNDM | Tandem Diabetes Care Inc | $1,841,000 | -18.8% | 209,000 | 0.0% | 0.29% | +7.7% | |
| MRTX | Mirati Therapeutics Inc | $1,721,000 | +9.3% | 50,000 | 0.0% | 0.27% | +45.0% | |
| ARRY | Array BioPharma Inc | $1,687,000 | -36.8% | 370,000 | 0.0% | 0.27% | -15.9% | |
| TTPH | Buy | Tetraphase Pharmaceuticals Inc | $1,679,000 | -67.0% | 225,000 | +109.5% | 0.27% | -56.2% |
| ANTH | Sell | Anthera Pharmaceuticals Inc | $1,523,000 | -71.5% | 250,000 | -59.7% | 0.24% | -62.1% |
| DVAX | Sell | Dynavax Technologies Corp | $1,350,000 | -53.1% | 55,000 | -55.2% | 0.22% | -37.9% |
| RGLS | New | Regulus Therapeutic Inc | $1,308,000 | – | 200,000 | +100.0% | 0.21% | – |
| HOLX | Sell | Hologic Inc | $1,303,000 | -63.2% | 33,301 | -64.2% | 0.21% | -51.1% |
| AAVL | Avalanche Biotechnologies Inc | $1,269,000 | -49.3% | 154,006 | 0.0% | 0.20% | -32.7% | |
| THLD | Threshold Pharmaceuticals | $820,000 | +0.7% | 201,537 | 0.0% | 0.13% | +33.7% | |
| BINDQ | BIND Therapeutics Inc | $596,000 | -20.1% | 133,535 | 0.0% | 0.10% | +5.6% | |
| EPZM | Exit | Epizyme Inc | $0 | – | -131,785 | -100.0% | -0.38% | – |
| TMO | Exit | Thermo Fisher Scientific Inc | $0 | – | -37,000 | -100.0% | -0.58% | – |
| AMSG | Exit | Amsurg Corp | $0 | – | -70,000 | -100.0% | -0.59% | – |
| THOR | Exit | Thoratec Corp | $0 | – | -110,000 | -100.0% | -0.59% | – |
| RCPT | Exit | Receptos Inc | $0 | – | -28,000 | -100.0% | -0.64% | – |
| TEVA | Exit | Teva Pharma Ind Ltd ADR repr 1 Shareadr | $0 | – | -92,000 | -100.0% | -0.65% | – |
| VRX | Exit | Valeant Pharm Intl Inc | $0 | – | -32,248 | -100.0% | -0.86% | – |
| JNJ | Exit | Johnson & Johnson | $0 | – | -191,000 | -100.0% | -2.24% | – |
| BIIB | Exit | Biogen Inc | $0 | – | -50,291 | -100.0% | -2.44% | – |
| Exit | Select Sector SPDR Tr SBI Healthcareput | $0 | – | -700,000 | -100.0% | -6.25% | – | |
| Exit | iShares Tr Nasdaq Biotech ETFput | $0 | – | -200,000 | -100.0% | -8.86% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-10-26
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.